Maria Siemionow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maria Siemionow has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Klimczak
Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland
17 shared publications Antonio Rampazzo
Institute of Dermatology and Plastic Surgery, Cleveland Clinic, Cleveland, OH
7 shared publicationsBahar Bassiri Gharb
Institute of Dermatology and Plastic Surgery, Cleveland Clinic, Cleveland, OH 44195, USA
7 shared publicationsSerdar Nasir
Department of Plastic Surgery, Cleveland Clinic, Cleveland, OH
7 shared publicationsChad R. Gordon
6 shared publications- Dariusz Iżycki
Department of Cancer Immunology, Poznan University of Medical Sciences, 61-866 Poznań, Poland
6 shared publications
Latest Publications
- Open Access
- 1 October 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (10) , 2750-2764
A Four-Year Pathology Review of the Near Total Face Transplant
- 1 October 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (10) , 2750-2764
Open AccessA Four-Year Pathology Review of the Near Total Face Transplant
- 27 May 2013
- Published by Wolters Kluwer Health in Transplantation
- Vol. 95 (10) , 1197-1203
Effectiveness of Topical Immunosuppressants in Prevention and Treatment of Rejection in Face Allotransplantation
Background The use of topical immunosuppressants has been anecdotally reported for the treatment of rejection in vascularized composite allotransplantation. The aim of this study was to evaluate the effectiveness of topical tacrolimus and clobetasol in the prevention and treatment of rejection. Methods Seventy-six hemiface allotransplants, between ACI (RT1a) donors and Lewis (RT1l) recipients, were performed in 11 groups and treated with topical tacrolimus or clobetasol, or in combination with systemic cyclosporine A and anti–αβ–T-cell receptor antibody for 1 week. Topical treatment increased the survival of the allograft in all groups. Results Best outcomes were obtained in the groups treated with systemic therapy and topical tacrolimus. Expression of proinflammatory cytokines interleukin 2, interferon γ, tumor necrosis factor α, and transforming growth factor β correlated with clinical signs of rejection and the final outcomes. Clobetasol application was associated with a marked depletion of lymphocytic populations, and dermal and epidermal atrophy. Conclusions Both topical tacrolimus and clobetasol were effective in treating episodes of acute rejection, and the best outcomes were achieved when their application was initiated after systemic immunosuppression. Topical tacrolimus proved to be a preferable adjunct agent to the systemic therapy by preventing both the local and systemic complications.
- 27 May 2013
- Published by Wolters Kluwer Health in Transplantation
- Vol. 95 (10) , 1197-1203
Effectiveness of Topical Immunosuppressants in Prevention and Treatment of Rejection in Face Allotransplantation
Background The use of topical immunosuppressants has been anecdotally reported for the treatment of rejection in vascularized composite allotransplantation. The aim of this study was to evaluate the effectiveness of topical tacrolimus and clobetasol in the prevention and treatment of rejection. Methods Seventy-six hemiface allotransplants, between ACI (RT1a) donors and Lewis (RT1l) recipients, were performed in 11 groups and treated with topical tacrolimus or clobetasol, or in combination with systemic cyclosporine A and anti–αβ–T-cell receptor antibody for 1 week. Topical treatment increased the survival of the allograft in all groups. Results Best outcomes were obtained in the groups treated with systemic therapy and topical tacrolimus. Expression of proinflammatory cytokines interleukin 2, interferon γ, tumor necrosis factor α, and transforming growth factor β correlated with clinical signs of rejection and the final outcomes. Clobetasol application was associated with a marked depletion of lymphocytic populations, and dermal and epidermal atrophy. Conclusions Both topical tacrolimus and clobetasol were effective in treating episodes of acute rejection, and the best outcomes were achieved when their application was initiated after systemic immunosuppression. Topical tacrolimus proved to be a preferable adjunct agent to the systemic therapy by preventing both the local and systemic complications.
- 9 April 2013
- Published by Wiley in Microsurgery
- Vol. 33 (4) , 318-328
Techniques and materials for enhancement of peripheral nerve regeneration: A literature review
Peripheral nerve surgery performed under unfavorable conditions results in increased scar formation and suboptimal clinical outcomes. Providing the operated nerve with a protective barrier, reduces fibrosis and adhesion formation and may lead to improved outcomes. The ideal coverage material should prevent scar and adhesion formation, and maintain nerve gliding during motion. Nerve protection using autologous tissues has shown good results, but shortcomings include donor site morbidity and limited availability. Various types of methods and materials have been used to protect nerves. There are both advantages and disadvantages associated with the various materials and techniques. In this report we summarize currently used protective materials applied for nerve coverage under various surgical conditions. © 2013 Wiley Periodicals, Inc. Microsurgery, 2013.
- 9 April 2013
- Published by Wiley in Microsurgery
- Vol. 33 (4) , 318-328
Techniques and materials for enhancement of peripheral nerve regeneration: A literature review
Peripheral nerve surgery performed under unfavorable conditions results in increased scar formation and suboptimal clinical outcomes. Providing the operated nerve with a protective barrier, reduces fibrosis and adhesion formation and may lead to improved outcomes. The ideal coverage material should prevent scar and adhesion formation, and maintain nerve gliding during motion. Nerve protection using autologous tissues has shown good results, but shortcomings include donor site morbidity and limited availability. Various types of methods and materials have been used to protect nerves. There are both advantages and disadvantages associated with the various materials and techniques. In this report we summarize currently used protective materials applied for nerve coverage under various surgical conditions. © 2013 Wiley Periodicals, Inc. Microsurgery, 2013.
- Open Access
- 14 March 2013
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2013, 1-12
Chimerism-Based Experimental Models for Tolerance Induction in Vascularized Composite Allografts: Cleveland Clinic Research Experience
The preclinical experimental models of vascularized composite allografts (VCAs) have been rapidly developed for the assessment of immunomodulatory protocols for clinical application. Recently, researchers have focused on immunomodulatory protocols which overcome the immunologic barrier between the allogeneic donor and recipient and may lead to tolerance induction. In order to test the feasibility of chimerism induction, experimental VCAs have been performed in different models including rodents, large animals, and nonhuman primates. These models differ in the complexity of transplanted tissue and in their responses to immunomodulatory protocols. In most applications, VCA contains multiple-tissue components; however, each individual component of CTA possesses unique immunologic characteristics that ultimately contribute to the chimerism induction and successful outcome of the VCA. Heterogenic character and complexity of tissue components in different VCA models determine the quality and robustness of donor-specific chimerism. As introduced in experimental studies, variable immunomodulatory options have been studied to achieve tolerance to VCA in rodents and large animal models allowing for widespread application in clinic. In this paper, based on our own experience, we have analyzed the current knowledge of tolerance-inducing strategies via chimerism induction in VCA experimental models in the context of immunomodulatory protocols and VCA complexity and their relevance and applicability to clinical practice.
- 14 March 2013
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2013, 1-12
Open AccessChimerism-Based Experimental Models for Tolerance Induction in Vascularized Composite Allografts: Cleveland Clinic Research Experience
The preclinical experimental models of vascularized composite allografts (VCAs) have been rapidly developed for the assessment of immunomodulatory protocols for clinical application. Recently, researchers have focused on immunomodulatory protocols which overcome the immunologic barrier between the allogeneic donor and recipient and may lead to tolerance induction. In order to test the feasibility of chimerism induction, experimental VCAs have been performed in different models including rodents, large animals, and nonhuman primates. These models differ in the complexity of transplanted tissue and in their responses to immunomodulatory protocols. In most applications, VCA contains multiple-tissue components; however, each individual component of CTA possesses unique immunologic characteristics that ultimately contribute to the chimerism induction and successful outcome of the VCA. Heterogenic character and complexity of tissue components in different VCA models determine the quality and robustness of donor-specific chimerism. As introduced in experimental studies, variable immunomodulatory options have been studied to achieve tolerance to VCA in rodents and large animal models allowing for widespread application in clinic. In this paper, based on our own experience, we have analyzed the current knowledge of tolerance-inducing strategies via chimerism induction in VCA experimental models in the context of immunomodulatory protocols and VCA complexity and their relevance and applicability to clinical practice.
- 14 November 2012
- Published by Wiley in Microsurgery
- Vol. 33 (2) , 134-140
Pre‐ and postischemic pulsed acoustic cellular expression conditioning modulates expression of inflammation factors in cremaster ischemia/reperfusion injury model
Pulsed acoustic cellular expression (PACE) is a treatment that applies focused acoustic shock waves to promote tissue healing. The aim of this study was to assess the effect of PACE treatment on inflammatory responses in a cremaster muscle ischemia/reperfusion injury model. Seventeen cremaster muscle flaps were evaluated in four groups: nonischemic controls (n = 5), 5‐hour ischemia controls (n = 4), preischemic (5‐hour) PACE conditioning (n = 4), and postischemic (5‐hour) PACE conditioning (n = 4). The expression of proinflammatory cytokines (TNFα, IL‐6, IL‐1α, IL‐1β, GM‐CSF) and chemokines (CCL3, CCL4, CXCL4) was assessed using TaqMan® real‐time PCR. Expression of ELAM‐1, VCAM‐1, and ICAM‐1 was assessed by immunostaining. Preischemic PACE conditioning upregulated expression of IL‐6, CCL3, CCL4, and CXCL4, and downregulated expression of TNFα, GM‐CSF, and IL‐1α. Postischemic PACE conditioning significantly decreased expression of all evaluated genes. Pre‐ and postischemic PACE conditioning decreased expression of ELAM‐1 and ICAM‐1. Results of the study indicate that application of PACE conditioning may have a beneficial effect on the recovery of tissues subjected to the ischemia/reperfusion injury. Postischemic PACE conditioning revealed anti‐inflammatory effect as confirmed by decreased expression of inflammatory cytokines, chemokines, and cell adhesion molecules (ELAM‐1 and ICAM‐1) that are responsible for leukocyte recruitment into ischemic tissues. Hence, PACE therapy may be used effectively in clinical practice as a convenient therapeutic strategy to protect tissues against ischemia/reperfusion related injury after microsurgical procedures of free tissue transfers. © 2012 Wiley Periodicals, Inc. Microsurgery, 2013.
- 14 November 2012
- Published by Wiley in Microsurgery
- Vol. 33 (2) , 134-140
Pre‐ and postischemic pulsed acoustic cellular expression conditioning modulates expression of inflammation factors in cremaster ischemia/reperfusion injury model
Pulsed acoustic cellular expression (PACE) is a treatment that applies focused acoustic shock waves to promote tissue healing. The aim of this study was to assess the effect of PACE treatment on inflammatory responses in a cremaster muscle ischemia/reperfusion injury model. Seventeen cremaster muscle flaps were evaluated in four groups: nonischemic controls (n = 5), 5‐hour ischemia controls (n = 4), preischemic (5‐hour) PACE conditioning (n = 4), and postischemic (5‐hour) PACE conditioning (n = 4). The expression of proinflammatory cytokines (TNFα, IL‐6, IL‐1α, IL‐1β, GM‐CSF) and chemokines (CCL3, CCL4, CXCL4) was assessed using TaqMan® real‐time PCR. Expression of ELAM‐1, VCAM‐1, and ICAM‐1 was assessed by immunostaining. Preischemic PACE conditioning upregulated expression of IL‐6, CCL3, CCL4, and CXCL4, and downregulated expression of TNFα, GM‐CSF, and IL‐1α. Postischemic PACE conditioning significantly decreased expression of all evaluated genes. Pre‐ and postischemic PACE conditioning decreased expression of ELAM‐1 and ICAM‐1. Results of the study indicate that application of PACE conditioning may have a beneficial effect on the recovery of tissues subjected to the ischemia/reperfusion injury. Postischemic PACE conditioning revealed anti‐inflammatory effect as confirmed by decreased expression of inflammatory cytokines, chemokines, and cell adhesion molecules (ELAM‐1 and ICAM‐1) that are responsible for leukocyte recruitment into ischemic tissues. Hence, PACE therapy may be used effectively in clinical practice as a convenient therapeutic strategy to protect tissues against ischemia/reperfusion related injury after microsurgical procedures of free tissue transfers. © 2012 Wiley Periodicals, Inc. Microsurgery, 2013.
- 1 November 2012
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 69 (5) , 575-579
Application of Cell-Based Therapies in Facial Transplantation
The main purpose of cellular therapy application in face transplantation is the continuous need for the development of new strategies that would eliminate the use of toxic immunosuppressive protocols. Cellular therapy in transplantation can significantly benefit allograft survival and shorten healing time. Cells used for a therapeutic purpose are isolated mostly from bone marrow and adipose tissues. They have the ability to proliferate and differentiate in the transplanted tissue and have immunomodulatory activity. Most of the cellular therapies such as T-regulatory, dendritic, and chimeric cells are still in the experimental stage. Molecular characterization of these cells and the mechanism of their participation in allograft acceptance and rejection are not well established and will contribute to the future of modern transplantology.
- 1 November 2012
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 69 (5) , 575-579
Application of Cell-Based Therapies in Facial Transplantation
The main purpose of cellular therapy application in face transplantation is the continuous need for the development of new strategies that would eliminate the use of toxic immunosuppressive protocols. Cellular therapy in transplantation can significantly benefit allograft survival and shorten healing time. Cells used for a therapeutic purpose are isolated mostly from bone marrow and adipose tissues. They have the ability to proliferate and differentiate in the transplanted tissue and have immunomodulatory activity. Most of the cellular therapies such as T-regulatory, dendritic, and chimeric cells are still in the experimental stage. Molecular characterization of these cells and the mechanism of their participation in allograft acceptance and rejection are not well established and will contribute to the future of modern transplantology.
- 1 October 2012
- Published by Elsevier in Clinics in Plastic Surgery
- Vol. 39 (4) , 425-434
Impact of Reconstructive Transplantation on the Future of Plastic and Reconstructive Surgery
- 1 October 2012
- Published by Elsevier in Clinics in Plastic Surgery
- Vol. 39 (4) , 425-434
Impact of Reconstructive Transplantation on the Future of Plastic and Reconstructive Surgery
- 23 July 2012
- Published by Wiley in Microsurgery
- Vol. 33 (1) , 43-50
Composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin allotransplantation model of bone marrow transplantation
Cellular and vascularized bone marrow cells have been used to induce donor‐specific chimerism in various models of composite tissue allotransplantation. Although thymus transplantation has been reported in the literature, the effect of thymus transplantation on chimerism levels in vascularized bone containing composite tissue allotransplantation has not been reported. In this study, a new method for composite vascularized sternal bone marrow transplant model is descried that can be applied to augment chimerism after transplantation. A total of seven composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin transplantations were performed in two groups. The first group (n = 5) was designed as an allotransplantation group and the second group (n = 2) was designed as an isotransplantation group. Composite osseomusculocutaneous sternum, ribs, thymus, and pectoralis muscles allografts were harvested on thecommon carotid artery and external jugular vein and a heterotopic transplantation was performed to the inguinal region of the recipient rat. Cyclosporine A monotherapy was administered in order to prevent acute and chronic allograft rejection. Animals sacrificed when any sign of rejection occurred. The longest survival was 156 day post‐transplant. Assessment of bone marrow cells within sternum bone component and flow cytometry analysis of donor‐specific chimerism in the peripheral blood of recipients were evaluated. Our results showed that thiscomposite allograft carried 7.5 × 106 of viable hematopoietic cells within the sternum component. At day 7 post‐transplant chimerism was developed in T‐cell population and mean level was assessed at 2.65% for RT1n/CD4 and at 1.0% for RT1n/CD8. In this study, a newosseomusculocutaneous sternum, ribs, thymus, pectoralis muscle, and skin allotransplantation model is reported which can be usedto augment hematopoietic activity for chimerism induction after transplantation. © 2012 Wiley Periodicals, Inc. Microsurgery, 2013.
- 23 July 2012
- Published by Wiley in Microsurgery
- Vol. 33 (1) , 43-50
Composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin allotransplantation model of bone marrow transplantation
Cellular and vascularized bone marrow cells have been used to induce donor‐specific chimerism in various models of composite tissue allotransplantation. Although thymus transplantation has been reported in the literature, the effect of thymus transplantation on chimerism levels in vascularized bone containing composite tissue allotransplantation has not been reported. In this study, a new method for composite vascularized sternal bone marrow transplant model is descried that can be applied to augment chimerism after transplantation. A total of seven composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin transplantations were performed in two groups. The first group (n = 5) was designed as an allotransplantation group and the second group (n = 2) was designed as an isotransplantation group. Composite osseomusculocutaneous sternum, ribs, thymus, and pectoralis muscles allografts were harvested on thecommon carotid artery and external jugular vein and a heterotopic transplantation was performed to the inguinal region of the recipient rat. Cyclosporine A monotherapy was administered in order to prevent acute and chronic allograft rejection. Animals sacrificed when any sign of rejection occurred. The longest survival was 156 day post‐transplant. Assessment of bone marrow cells within sternum bone component and flow cytometry analysis of donor‐specific chimerism in the peripheral blood of recipients were evaluated. Our results showed that thiscomposite allograft carried 7.5 × 106 of viable hematopoietic cells within the sternum component. At day 7 post‐transplant chimerism was developed in T‐cell population and mean level was assessed at 2.65% for RT1n/CD4 and at 1.0% for RT1n/CD8. In this study, a newosseomusculocutaneous sternum, ribs, thymus, pectoralis muscle, and skin allotransplantation model is reported which can be usedto augment hematopoietic activity for chimerism induction after transplantation. © 2012 Wiley Periodicals, Inc. Microsurgery, 2013.
- 1 January 2012
- Published by Springer Nature
- p. 303-309
Burn reconstruction — Future perspectives: Facial transplantation
- 1 January 2012
- Published by Springer Nature
- p. 303-309
Burn reconstruction — Future perspectives: Facial transplantation
- 1 January 2012
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 23 (1) , 254-259
Face Transplantation
Since 2005, 17 facial allotransplantations have been performed worldwide. The brief summary of current cases with ongoing concerns is presented in this article. Fifteen publications were reported for 10 facial allotransplantations. For the remaining 7 transplantations, information was gathered from scientific meeting presentations and media releases. The summary of current cases in terms of etiology, indications, results, complications, and outcomes are based on these data. The discussion of ongoing concerns, controversies, and overview of future implications is accomplished by reviewing the literature of ethical debates, experimental studies, clinical studies, and personal opinion. Two of the 17 face transplant recipients died. Overall survival rate was 88%. No early graft loss due to technical failure was reported. All reported cases that have more than 1-year follow-up had at least 1 acute rejection episode, which was reversible with treatment. Opportunistic infections and metabolic complications were observed as adverse effects. Motor recoveries were slower than the sensorial recoveries, as expected. Functional and aesthetic outcomes were satisfactory. Concerns and controversies about concomitant face and hand transplantation, recipient blindness, recipient age, primary reconstruction option in facial trauma cases, funding, graft failure risks, and future treatment options are discussed. Because of uncertainty about long-term outcomes, immunosuppression-related concerns and ethical debates limit worldwide application of facial allotransplantation. However, in selected group of patients, it is a unique reconstruction method with promising outcomes. Further research and investigation in transplant immunology and treatment hold the key to advance this treatment option.
- 1 January 2012
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 23 (1) , 254-259
Face Transplantation
Since 2005, 17 facial allotransplantations have been performed worldwide. The brief summary of current cases with ongoing concerns is presented in this article. Fifteen publications were reported for 10 facial allotransplantations. For the remaining 7 transplantations, information was gathered from scientific meeting presentations and media releases. The summary of current cases in terms of etiology, indications, results, complications, and outcomes are based on these data. The discussion of ongoing concerns, controversies, and overview of future implications is accomplished by reviewing the literature of ethical debates, experimental studies, clinical studies, and personal opinion. Two of the 17 face transplant recipients died. Overall survival rate was 88%. No early graft loss due to technical failure was reported. All reported cases that have more than 1-year follow-up had at least 1 acute rejection episode, which was reversible with treatment. Opportunistic infections and metabolic complications were observed as adverse effects. Motor recoveries were slower than the sensorial recoveries, as expected. Functional and aesthetic outcomes were satisfactory. Concerns and controversies about concomitant face and hand transplantation, recipient blindness, recipient age, primary reconstruction option in facial trauma cases, funding, graft failure risks, and future treatment options are discussed. Because of uncertainty about long-term outcomes, immunosuppression-related concerns and ethical debates limit worldwide application of facial allotransplantation. However, in selected group of patients, it is a unique reconstruction method with promising outcomes. Further research and investigation in transplant immunology and treatment hold the key to advance this treatment option.